Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Exelixis Inc Market Cap
The Exelixis Inc (EXEL) share price is expected to decrease by 8.85% over the next year. This is based on calculating the average 12-month share price estimate provided by 22 stock analysts who have covered EXEL. Price targets range from $18.9 at the low end to $38 at the high end. The current analyst consensus for EXEL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 22 Wall Street analysts have assignedEXEL 14 buy ratings, 6 hold ratings, and 2 sell ratings. This means that analysts expect Exelixis Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EXEL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of EXEL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Derek Archila Wells Fargo | Overweight | $36 | Maintains | Oct 30, 2024 |
| Gregory Renza RBC Capital | Outperform | $34 | Reiterates | Oct 30, 2024 |
| Asthika Goonewardene Truist Securities | Buy | $38 | Maintains | Oct 30, 2024 |
| Sudan Loganathan Stephens & Co. | Equal-Weight | $29 | Maintains | Oct 30, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $36 | Maintains | Oct 30, 2024 |
| Etzer Darout BMO Capital | Outperform | $36 | Maintains | Oct 30, 2024 |
| Michael Schmidt Guggenheim | Buy | $33 | Maintains | Oct 30, 2024 |
| Yaron Werber TD Cowen | Buy | $34 | Maintains | Oct 21, 2024 |
| Silvan Tuerkcan JMP Securities | Market Outperform | $34 | Maintains | Oct 16, 2024 |
| Stephen Willey Stifel | Hold | $30 | Maintains | Oct 16, 2024 |
| Gregory Renza RBC Capital | Outperform | $34 | Maintains | Oct 16, 2024 |
| Jason Gerberry B of A Securities | Buy | $32 | Maintains | Oct 15, 2024 |
| Silvan Tuerkcan JMP Securities | Market Outperform | $29 | Reiterates | Oct 11, 2024 |
| Jefferson Harralson Morgan Stanley | Equal-Weight | $28 | Maintains | Oct 11, 2024 |
| Gregory Renza RBC Capital | Outperform | $30 | Maintains | Oct 4, 2024 |
| Gregory Renza RBC Capital | Outperform | $27 | Reiterates | Sep 26, 2024 |
| Silvan Tuerkcan JMP Securities | Market Outperform | $29 | Reiterates | Sep 20, 2024 |
| Ashwani Verma UBS | Neutral | $30 | Initiates | Sep 19, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $29 | Reiterates | Sep 18, 2024 |
| Asthika Goonewardene Truist Securities | Buy | $33 | Reiterates | Aug 8, 2024 |
When did it IPO
2000
Staff Count
1,310
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Michael M. Morrissey Ph.D.
Market Cap
$10.23B
In 2023, EXEL generated $1.83B in revenue, which was a increase of 13.60% from the previous year. This can be seen as a signal that EXEL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Exelixis (EXEL) demonstrates above-average financial growth, indicating a strong potential to outperform the market.
Why It Matters - Exelixis's above-average financial growth suggests potential for higher returns, making it an attractive investment opportunity compared to market peers.
Sat, 07 Dec 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - In 2024, the SPDR S&P Biotech ETF has gained 9%, underperforming the S&P 500's 28% increase, indicating a lag in the biotech sector relative to the broader market.
Why It Matters - The biotech sector's underperformance signals potential investment opportunities, as it may rebound, offering higher returns compared to the broader market.
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Exelixis (EXEL) and Incyte (INCY) are notable stocks in the Biomedical and Genetics sector, attracting interest from value investors.
Why It Matters - Comparing Exelixis and Incyte helps investors identify potentially undervalued stocks in the biomedical sector, guiding investment decisions based on value metrics.
Thu, 28 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Exelixis (EXEL) reported earnings 30 days ago; investors may want to monitor upcoming developments and stock performance indicators for future trends.
Why It Matters - Upcoming developments and market reactions following Exelixis' recent earnings report can influence stock performance, affecting investment decisions and valuations.
Fri, 29 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Premium offers Style Scores to help investors identify strong stocks, catering to value, growth, and momentum strategies.
Why It Matters - The Zacks Style Scores can streamline stock selection for various investment strategies, potentially enhancing portfolio performance and aiding in more informed investment decisions.
Mon, 25 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters - The mention of Zacks Style Scores highlights a tool for identifying high-potential stocks, aiding investors in making informed decisions to enhance portfolio performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
